11.4% reported weight loss · 1% loss with placebo · 36 weeks
120 mg once daily
Adults with obesity or overweight and comorbidity without diabetes
Treatment-regimen estimand includes post-intercurrent-event data regardless of adherence. Missing data imputation assumes accrued benefit is retained with no further benefit after an event. Extended Data Table 2 independently verifies 11.4% active versus 1.0% placebo. Investigational; first patients dosed in phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 by August 6, 2026.
Safety context
GI events predominate; 10.4% AE-related treatment discontinuation across active arms; no drug-induced liver injury observed.
Limitations: 120 mg efficacy result has a source conflict: the June 24 publisher correction changes Figure 3b from 12.1% to 12.7%, while current article text, Figure 3a source data, and downloadable XLSX still show 12.1%. The treatment-regimen 11.4% result in Extended Data Table 2 is unaffected. Do not substitute the conflicting efficacy figure.
Least-squares mean change from a mixed model for repeated measures.
Safety context
At 90 mg, 96.2% reported an adverse event versus 44.4% with placebo. Nausea/vomiting predominated; no treatment-related serious events. One of 36 treated diabetes participants stopped due to a drug-related event.
Limitations: Small early cohort. The headline 1.02 pp figure is placebo-adjusted; the active-arm decrease was 0.84 pp.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Structure reported ACCESS open-label extension results. This extension involved continuing participants and placebo crossover, not a new parallel placebo-controlled comparison.
